Half of All Deaths Trace Back to the Same Process

Why acute inflammation is a controlled demolition rather than an accident, why the shutdown phase is an active program that can fail, what a CRP number actually measures and what it cannot tell you, and how a survival response running at one percent intensity for thirty years taxes the arteries, the metabolism, and the brain.

The swelling around a sprained ankle is not the injury.

Created by Paperbanana.org

Roll your ankle stepping off a curb, and within an hour, the joint is hot, red, tight, and painful to stand on. Every one of those sensations was manufactured by your own body, deliberately, according to a program older than vertebrates. The ligament tore in a quarter of a second. The response to the tear takes a week, and it is doing something.

Most people carry a mental model of inflammation as a malfunction, a thing that flares up and must be brought down. Under that model, the word anti-inflammatory reads as an unambiguous good, and a high number on a blood test reads as damage in progress.

That model has the biology backward. Acute inflammation is one of the most tightly choreographed operations the body runs. It has an on switch, a peak, and a shutdown sequence that is every bit as engineered as the flare.

A 2019 perspective in Nature Medicine, assembled by twenty researchers across immunology, aging biology, and epidemiology, attributes more than half of all deaths worldwide to conditions with a chronic inflammatory component: ischemic heart disease, stroke, cancer, diabetes, chronic kidney disease, fatty liver disease, and the autoimmune and neurodegenerative disorders.1 Whatever is killing those people is a far weaker version of the ankle that simply never ends.

This article covers what acute inflammation is doing inside the tissue, why the shutdown is a program in its own right and what happens when it fails, what the CRP number on a lab report measures and how far it sits from the thing you care about, how one expensive trial separated the marker from the mechanism, where the low-grade version comes from in a person who is not sick, and what any of it changes about the decisions you make.

What Is Actually Happening Inside a Sprained Ankle

A pipe bursts on the third floor of an office building. The crew that shows up does not tiptoe. They shut the main, cut open the drywall, pull up the carpet, and run loud industrial fans for three days. When they leave, the hallway looks considerably worse than the leak did. All that mess is the repair.

Your ankle runs the same operation. When the ligament tears, cells rupture and the extracellular matrix shreds, releasing molecules that are supposed to stay inside cells. Immune sentinels already living in that tissue, mast cells and resident macrophages, detect those molecules as evidence that something broke.

Their first move is to open the plumbing. Local arterioles dilate, so more blood arrives, which is the heat and the redness. The walls of the capillaries and small veins loosen their junctions and become leaky, so plasma floods out into the tissue, which is the swelling. The swelling is how the delivery happens. Plasma carries clotting factors, complement proteins, and antibodies into a space that blood does not normally reach.

Then the tissue starts recruiting. The cells lining the vessel wall put adhesion molecules on their surface, which act like Velcro. Neutrophils traveling in the bloodstream catch on that surface, roll to a stop, flatten, and squeeze between the endothelial cells into the tissue itself. Within hours, there are millions of them where there were none.

The pain has a job too. Prostaglandins and bradykinin released at the site lower the firing threshold of nearby nerve endings, so pressure that would normally register as nothing registers as pain. That is behavioral enforcement, and it is what stops you from walking on a torn ligament for the week it needs to knit.

Cornelius Celsus wrote down the four outward signs in the first century: calor, rubor, tumor, dolor. Heat, redness, swelling, pain. We have known the outside of this for two thousand years. The inside took until the last several decades, and every symptom on Celsus’s list turned out to be a deliverable rather than a defect.

The Shutdown Is a Separate Program

The ankle is better in a week. What turned it off?

The intuitive answer is that the stimulus goes away, the mediators wash out, and the crew drifts home. The fire runs out of fuel. That was essentially the textbook answer for most of the twentieth century, and it is wrong.2

A fire department does not end a call by driving away when the flames stop. There is a second operation with its own name, overhaul, and its own orders. Crews go back into the structure hunting for hidden fire, pull ceilings, salvage what can be saved, ventilate the smoke, and account for every person who went in. It is a different shift doing different work, and skipping it is how buildings reignite at three in the morning.

Beginning in the 1990s, Charles Serhan’s laboratory at Harvard found the biochemical version of overhaul. During the resolution phase, the same enzymatic machinery that had been producing pro-inflammatory lipid signals from arachidonic acid switches its product line. It starts turning out a structurally different class of molecules: first lipoxins, and then, built from the omega-3 fatty acids EPA and DHA, the resolvins, protectins, and maresins. Serhan’s group named the family specialized pro-resolving mediators.2

These molecules are doing active work. New neutrophils stop arriving. The ones already in the tissue receive instructions to undergo programmed cell death, and macrophages show up to eat the corpses, a process with its own name, efferocytosis. Somewhere in there, the macrophages themselves get reprogrammed from an inflammatory phenotype into a repair phenotype, then routed out of the tissue through the lymphatics. Resolution is a staffed, scheduled, actively signaled shutdown.

Carl Nathan and Aihao Ding argued in Cell in 2010 that persistent inflammation frequently reflects a failure of resolution rather than an excess of initiation, and that inflammation can persist for reasons that have nothing to do with the original trigger still being present.3 Chronic inflammation, in that image, is the building where the emergency crew never left: fans still running, drywall still open, hallway still torn up, thirty years after somebody fixed the pipe.

What a CRP Number Measures

Picture a factory in a distant city that manufactures emergency supplies. It has no eyes on any job site. It manufactures when the phone rings. The volume it ships tells you that a call came in and roughly how loud the caller was, and nothing at all about where the emergency is, what kind it is, or whether anyone is handling it.

The liver is that factory. The phone call is interleukin-6, a cytokine released by immune cells at the site of trouble. Hepatocytes carry IL-6 receptors, and when IL-6 arrives, they ramp up transcription of a set of proteins called acute phase reactants. C-reactive protein is the one that ended up on your lab report.

CRP sits two steps downstream of anything you care about: trouble, then IL-6, then liver, then CRP. Every property of the test follows from that position.

CRP is fast, and its range is enormous. Hepatic synthesis begins almost immediately after a stimulus, serum concentrations climb above 5 mg/L by about six hours, peak around forty-eight, and the plasma half-life is roughly nineteen hours. In a healthy young blood donor, the median sits at 0.8 mg/L. After an acute-phase stimulus, values can run from under 0.05 mg/L to above 500 mg/L, a ten-thousandfold swing.4 That half-life is short and, more usefully, constant in health and in disease, so the only thing setting the concentration in your blood is the rate at which the liver is making it. When the stimulus stops, the number falls.

The test cannot tell you where the call came from. CRP does not distinguish IL-6 arriving from pneumonia, a root canal, rheumatoid arthritis, a marathon, or abdominal fat. Pepys and Hirschfield published a correction to their own 2003 review specifically to sharpen this point: the CRP response is nonspecific, it is triggered by many disorders unrelated to cardiovascular disease, and using it for cardiovascular risk assessment requires first establishing a true baseline that is not distorted by whatever else happens to be going on.4

High-sensitivity CRP is not a different molecule. Standard CRP assays are calibrated for roughly the 10 to 1,000 mg/L range, which is the range of acute infection. The high-sensitivity assay measures the identical protein down to about 0.1 mg/L. The sensitivity is in the instrument rather than the biology, and what it buys you is the ability to read the bottom of the range, which is where chronic low-grade inflammation lives. The American Heart Association and the CDC published cutpoints in 2003 based on population tertiles: below 1 mg/L is the low-risk group, 1 to 3 mg/L is average, and above 3 mg/L is high.5 Anything above 10 mg/L is generally read as acute illness rather than baseline and repeated later.

The predictive power is substantial. The Emerging Risk Factors Collaboration pooled individual records for 160,309 people with no history of vascular disease across 54 long-term prospective studies, covering 1.31 million person-years and 27,769 fatal or nonfatal outcomes. CRP concentration tracked nearly log-linearly with the risk of ischemic vascular disease and with nonvascular mortality.6

The number predicts. Whether it causes is a different question entirely.

A collaboration of 47 studies across 15 countries tested that directly, using a design called Mendelian randomization. People inherit variants in the CRP gene that shift their lifelong CRP concentration by as much as 30 percent per allele, and those variants are inherited at conception. They are not entangled with diet, weight, smoking, or illness the way a measured CRP value is. Across 194,418 participants, including 46,557 with coronary heart disease, one standard deviation of genetically raised CRP carried a risk ratio for coronary heart disease of 1.00, with a confidence interval running from 0.90 to 1.13. The same one standard deviation of measured circulating CRP carried a risk ratio of 1.33. The two estimates disagreed at p = 0.001, and the authors concluded that CRP concentration itself is unlikely to be even a modest causal factor in coronary heart disease.7 A thermometer tracks a fever accurately. Nobody has ever brought a fever down by cooling the thermometer.

The Trial That Separated the Marker from the Mechanism

If CRP is a bystander, the question underneath it gets sharper. Is the inflammation that CRP reports also a bystander, or is it doing the damage?

For decades, that question had no clean answer, because everything that lowers inflammation lowers something else at the same time. Statins lower LDL and CRP together. Exercise moves body fat, blood pressure, insulin sensitivity, and CRP all at once, and losing weight moves everything essentially. There was no way to isolate the variable.

Paul Ridker at Brigham and Women’s Hospital had spent two decades circling one observation: roughly half of heart attacks happen to people whose cholesterol is not high. Something else is going on in those arteries, and the candidate was inflammation.

Testing it required a drug that hits inflammation and nothing else. Canakinumab is a monoclonal antibody that binds and neutralizes interleukin-1 beta, which sits one rung upstream of IL-6, which sits one rung upstream of CRP. It does not touch lipids at all.

CANTOS enrolled 10,061 patients who had already survived a heart attack and whose hs-CRP remained at 2 mg/L or above despite aggressive statin therapy. They were randomized to placebo or to one of three canakinumab doses, injected under the skin every three months, and followed for a median of 3.7 years. At forty-eight months, hs-CRP had fallen by 26 to 41 percent depending on dose, and IL-6 had fallen alongside it, while LDL cholesterol did not move. The 150 mg dose reduced the primary endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death, with a hazard ratio of 0.85.8

The effect was modest. There was no all-cause mortality benefit. Fatal infection was more common on the drug. Turn down a system whose day job is keeping you alive, and that is what you get. The drug was never approved for this indication, and its real contribution was closing a question that had been open for a century: reducing inflammation, and only inflammation, changed what happened in those arteries.

Where the Low-Grade Version Comes From

This leaves the part that applies to almost everyone reading this. If you have no infection, no autoimmune disease, and no splinter in your thumb, where are the IL-1 beta, the IL-6, and the TNF-alpha coming from?

For most of the twentieth century, adipose tissue was pictured as a storage unit, biologically boring, a warehouse where surplus calories sat until somebody needed them.

In 1993, Gokhan Hotamisligil, Narinder Shargill, and Bruce Spiegelman at Dana-Farber reported that adipose tissue in four separate rodent models of obesity and diabetes was overexpressing TNF-alpha, a cytokine everyone at the time filed under immune signaling. The protein was elevated locally in the fat and systemically in the blood. Then they neutralized TNF-alpha in obese rats and watched insulin-stimulated glucose uptake in the periphery improve significantly.9

The warehouse turned out to be an endocrine and immune organ. As fat tissue expands, particularly the visceral depot packed around the organs, it recruits macrophages. Those macrophages take on an inflammatory phenotype and surround the dying fat cells in formations that pathologists call crown-like structures. They secrete TNF-alpha, IL-6, and IL-1 beta into the local tissue and into the circulation. TNF-alpha then interferes with the signaling cascade downstream of the insulin receptor, and insulin resistance follows. The liver, which sits directly downstream of visceral fat’s venous drainage, gets the highest dose first.

The ankle was a bonfire that burned hot for a week and then got cleaned up. Visceral fat is a compost heap smoldering at roughly one percent of that intensity, in the middle of the body, continuously, for thirty years. The chemistry is the same chemistry, differing only in dose and duration, and toxicology has been built for five centuries on the observation that the dose makes the poison.

Age contributes its own baseline drift. Claudio Franceschi proposed in 2000 that aging itself carries a chronic low-grade inflammatory tone, which he named inflamm-aging.10 Cells that reach the end of their replicative lifespan do not always die quietly; senescent cells persist and secrete an inflammatory cocktail from wherever they are stuck. Damaged mitochondria leak molecules that look bacterial to the innate immune system, because mitochondria used to be bacteria. Decades of accumulated debris and lifetime pathogen exposure feed the same channel. Average CRP climbs with age in people who are not sick and never were.

Physical inactivity, disrupted sleep, chronic psychological stress, periodontal disease, ultra-processed diets, and environmental toxicants all push the same lever. Furman’s group cataloged them as the modifiable inputs to systemic chronic inflammation.1 Every item on that list is something a person can move.

The Same Signals Reach the Brain

Think about the last time you had the flu. You ached everywhere, including places the virus never went. Thinking straight was impossible. Food stopped being interesting, and so did conversation, and your phone, and everything else. What you wanted was a dark room and no visitors.

Ask most people what caused that, and they say the virus. The virus was replicating in your respiratory epithelium. It was not in your knees, and it was not in your motivation.

Robert Dantzer and colleagues formalized the alternative in a 2008 review in Nature Reviews Neuroscience: cytokines produced by the peripheral immune system act on the brain to run a coordinated behavioral program called sickness behavior.11 The withdrawal, the anhedonia, the loss of appetite, the fatigue, and the excess sleep are outputs of that program rather than incidental damage. They are the behavioral arm of the immune response, evolved to pull energy away from foraging and socializing and put it into fighting the pathogen.

The message reaches the brain by several roads. Vagal afferent nerves carry it up from the abdominal cavity. Cytokines cross at the circumventricular organs, where the blood-brain barrier is deliberately leaky. Microglia inside the brain then produce cytokines of their own, amplifying the signal locally.

The clinical evidence runs in the same direction. Patients given interferon-alpha for hepatitis C or melanoma develop clinical depression at strikingly high rates, in some series approaching a third. Depressed patients show elevated CRP, IL-6, and TNF-alpha compared with controls. Anti-TNF therapy improves mood in psoriasis, Crohn’s disease, and rheumatoid arthritis.

None of that means depression is inflammation, and this is a place where the popular version has run considerably ahead of the science. The elevation is an average across groups, and most depressed people do not have elevated inflammatory markers. Trials of anti-inflammatory drugs in unselected depression have been unimpressive. The signal appears in a subset, and identifying that subset in advance remains unsolved. What is established is narrower and still important: inflammation can produce depressive symptoms in a person who did not have them.

Sleep sits inside the same loop. Michael Irwin’s group at UCLA meta-analyzed 72 studies covering more than 50,000 people. Sleep disturbance was associated with higher CRP and higher IL-6, and so was the extreme of long sleep.12 The effect sizes were small, and the same review carries a complication worth stating plainly. When it pooled the experiments, where researchers take the sleep away on purpose and watch what happens, the association disappeared. Neither sleep deprivation nor sleep restriction moved CRP, IL-6, or TNF-alpha. The cohorts see the link consistently. The experiments have not caught it, and the direction of causation is still open.

What To Actually Do with This

Read a CRP number for what it is. Have it drawn when you are well and at least a couple of weeks clear of any infection, dental procedure, injury, or flare. A value above 10 mg/L is a report on this week, so repeat it once the week is over. Below 1, between 1 and 3, and above 3 are the AHA and CDC tiers.5 Treat the result as one input among several and hold onto the fact that driving the number down is not the objective, since the number is downstream of the thing worth changing.7

The exercise mechanism is not the one most people assume. Contracting muscle releases IL-6, and plasma IL-6 can rise as much as a hundredfold during prolonged exercise, more than any other cytokine. That looks like an inflammatory event and is not one. Muscle-derived IL-6 is triggered by energetic stress, meaning calcium signaling and glycogen depletion, and it travels a pathway independent of TNF-alpha entirely. Downstream, it stimulates the anti-inflammatory cytokines IL-1ra and IL-10 and suppresses TNF-alpha.13 Regular training lowers baseline CRP over months, and the pathway runs through the muscle fiber itself. The contraction is doing the work whether the scale cooperates.

On that note, the waist tells you more than the scale does. The visceral depot is the one that recruits macrophages and drains into the portal vein,9 and it responds to diet and training even in stretches when body weight barely moves.

Sleep belongs on the list with the caveat attached. The cohort association is consistent and small; the experimental evidence is not there yet.12 Whether repairing your sleep lowers your inflammation is a question the data has not answered, and anyone selling you the causal version is ahead of it.

Be careful what you mean by anti-inflammatory, because suppression and resolution are different operations. The COX-2 enzyme that produces the prostaglandins of the flare is the same enzyme that later class-switches to produce lipoxins. Shut COX down with a non-steroidal anti-inflammatory, and you can, in animal models, delay the resolution instead of speeding it up.2 CANTOS showed the cost at the other end, where turning down IL-1 beta raised fatal infections.8 Ira Tabas and Christopher Glass laid out the general problem in Science in 2013: the inflammatory response is required for survival, and its redundancy and compensatory pathways squeeze the risk-to-benefit ratio of any drug that suppresses it broadly.14 The field is moving toward resolution, meaning agonists that switch the shutdown program on rather than antagonists that hold the flare down.

Omega-3s deserve an honest paragraph. EPA and DHA are the literal substrate for resolvins, protectins, and maresins,2 a real mechanism and the reason fish oil keeps getting tested. The cardiovascular outcome trials have been genuinely mixed, with some large trials of purified high-dose EPA showing benefit and others showing nothing. The substrate biology is solid; the translation into a capsule with a measurable endpoint is not settled, and anyone who tells it to you has picked a side.

Which brings it back to the compost heap. Nothing on this list produces a dramatic result in a week, because the process it addresses is not dramatic in a week. Thirty years at one percent is the exposure that matters. The interventions are dose-and-duration interventions, too, and the reason to start any of them is not that you will feel it by Friday.

References

1. Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., Miller, A. H., Mantovani, A., Weyand, C. M., Barzilai, N., Goronzy, J. J., Rando, T. A., Effros, R. B., Lucia, A., Kleinstreuer, N., & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0

2. Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101. https://doi.org/10.1038/nature13479

3. Nathan, C., & Ding, A. (2010). Nonresolving inflammation. Cell, 140(6), 871–882. https://doi.org/10.1016/j.cell.2010.02.029

4. Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: A critical update. Journal of Clinical Investigation, 111(12), 1805–1812. https://doi.org/10.1172/JCI18921 (Corrigendum published 2003, Journal of Clinical Investigation, 112(2), 299)

5. Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., III, Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Jr., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45

6. Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M. B., Thompson, S. G., Collins, R., & Danesh, J. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. The Lancet, 375(9709), 132–140. https://doi.org/10.1016/S0140-6736(09)61717-7

7. C Reactive Protein Coronary Heart Disease Genetics Collaboration. (2011). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ, 342, d548. https://doi.org/10.1136/bmj.d548

8. Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., … Glynn, R. J. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/NEJMoa1707914

9. Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993). Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science, 259(5091), 87–91. https://doi.org/10.1126/science.7678183

10. Franceschi, C., Bonafè, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., & De Benedictis, G. (2000). Inflamm-aging: An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences, 908(1), 244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x

11. Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56. https://doi.org/10.1038/nrn2297

12. Irwin, M. R., Olmstead, R., & Carroll, J. E. (2016). Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry, 80(1), 40–52. https://doi.org/10.1016/j.biopsych.2015.05.014

13. Petersen, A. M. W., & Pedersen, B. K. (2005). The anti-inflammatory effect of exercise. Journal of Applied Physiology, 98(4), 1154–1162. https://doi.org/10.1152/japplphysiol.00164.2004

14. Tabas, I., & Glass, C. K. (2013). Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science, 339(6116), 166–172. https://doi.org/10.1126/science.1230720

Onward Together is growing!

In the welcome email, you will get a free booklet PDF that I created, so be sure to subscribe! It is very informative and based on my true life story.

The willpower-isn’t-finite breakdown, plus the body science underneath it.

Subscribe → https://onwardtogether.beehiiv.com/

Read Issue #1 → https://onwardtogether.beehiiv.com/p/issue-1-discipline-isn-t-a-battery-and-what-to-do-instead

Read Issue #2 → https://onwardtogether.beehiiv.com/p/issue-2-why-most-rest-isn-t-actually-restful

Read Issue #3 → https://onwardtogether.beehiiv.com/p/i-finally-finished-the-thing-i-promised-you

From now on, every issue will come out every Sunday!